{"componentChunkName":"component---gatsby-theme-buzzing-src-gatsby-theme-blog-core-templates-post-query-js","path":"/tweet/1341880899428888584","result":{"data":{"site":{"siteMetadata":{"title":"Reddit 热门","description":"用中文浏览Reddit热门内容","social":[{"name":"Reddit","url":"https://www.reddit.com/","external":true,"prefetch":null},{"name":"GitHub","url":"https://github.com/gatsbyjs","external":null,"prefetch":null}],"menuLinks":[{"name":"每周精选","url":"/issues","external":null,"prefetch":null},{"name":"RSS","url":"/rss.xml","external":null,"prefetch":false}],"localize":[{"title":"Buzzing on Reddit","description":"See what's buzzing on Reddit in your native language","locale":"en","social":[{"name":"Reddit","url":"https://www.reddit.com/","external":true,"prefetch":null}],"menuLinks":[{"name":"Weekly Selection","url":"/issues","external":null,"prefetch":null},{"name":"RSS","url":"/rss.xml","external":null,"prefetch":false}]},{"title":"Reddit 熱門","description":"用中文瀏覽Reddit熱門內容","locale":"zh-Hant","social":null,"menuLinks":null}]}},"blogPost":{"__typename":"SocialMediaPost","id":"TweetPost-1341880899428888584","excerpt":"","body":"Tech leading all S&amp;P 500 sectors for the 2nd year in a row with a 43% gain.\n\nFollowing the 50% gain in 2019 this the 2nd best 2-year performance ever for Tech after 1998-1999.\n\n$XLK\n\nData via @ycharts https://t.co/Jo1z8zkBsw","slug":"/tweet/1341880899428888584","title":"Tech leading all S&amp;P 500 sectors for the 2nd year in a row with a 43% gain.\n\nFollowing the 50% gain in 2019 this the 2nd best 2-year performance ever for Tech after 1998-1999.\n\n$XLK\n\nData via @ycharts https://t.co/Jo1z8zkBsw","tags":["tweet"],"date":"December 24, 2020","dateISO":"2020-12-24T12:35:30.000Z","datetime":"2020-12-24 12:35","image":null,"imageAlt":"Tweet Image","socialImage":null,"fields":{"basePath":"/"},"thirdPartyId":"1341880899428888584","provider":"Twitter","url":"https://twitter.com/charliebilello/statuses/1341880899428888584","originalUrl":null,"imageRemote":"https://pbs.twimg.com/media/Ep9RVqzXUAMzrWi.png","video":null,"channel":null,"channelUrl":null,"author":"Charlie Bilello","authorUrl":"https://twitter.com/charliebilello","authorImage":{"childImageSharp":{"fixed":{"base64":"data:image/png;base64,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","width":48,"height":48,"src":"/static/5639175a95b865308d660efccb2cf61d/aff39/N0sQdj76.png","srcSet":"/static/5639175a95b865308d660efccb2cf61d/aff39/N0sQdj76.png 1x,\n/static/5639175a95b865308d660efccb2cf61d/e5b88/N0sQdj76.png 1.5x,\n/static/5639175a95b865308d660efccb2cf61d/88b72/N0sQdj76.png 2x"}}},"authorSlug":"charliebilello","score":433,"views":null,"sharedCount":87,"likeCount":259,"sharedContent":null,"parent":{"__typename":"TweetJson","localize":[{"locale":"zh","full_text":"科技股以43%的涨幅连续第二年领跑所有标准普尔500指数板块。\n\n继2019年增长50%之后，这是Tech在1998-1999年后第二好的两年表现。\n\n$XLK\n\n通过@ycharts https://t.co/Jo1z8zkBsw提供的数据","quoted_status_full_text":null,"retweeted_status_full_text":null},{"locale":"zh-Hant","full_text":"科技股以43%的漲幅連續第二年領跑所有標準普爾500指數板塊。\n\n繼2019年增長50%之後，這是Tech在1998-1999年後第二好的兩年表現。\n\n$XLK\n\n通過@ycharts https://t.co/Jo1z8zkBsw提供的數據","quoted_status_full_text":null,"retweeted_status_full_text":null}]}},"previous":{"id":"TweetPost-1341931475260895236","excerpt":"","slug":"/tweet/1341931475260895236","title":"A Short History of Chasing the Best Performing Funds\n\nThis one is for all the new ARKK shareholders\n\nhttps://t.co/gvF4Q7HzGx","date":"December 24, 2020","__typename":"SocialMediaPost","parent":{"__typename":"TweetJson","localize":[{"locale":"zh","full_text":"追逐业绩最佳基金简史\n\n这是献给方舟的所有新股东\n\nhttps://t.co/gvF4Q7HzGx","quoted_status_full_text":null,"retweeted_status_full_text":null},{"locale":"zh-Hant","full_text":"追逐業績最佳基金簡史\n\n這是獻給方舟的所有新股東\n\nhttps://t.co/gvF4Q7HzGx","quoted_status_full_text":null,"retweeted_status_full_text":null}]}},"next":{"id":"RedditPost-kjexi6","excerpt":"Just released!\n\n * 100% cellular response in the 2 mg group\n * Grade 1 adverse side effects = Redness at injection site/erythema\n\nhttps://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30433-8/fulltext\n[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20]30433-8/fulltext)","slug":"/reddit/r/stocks/comments/kjexi6/inovio_pharmaceuticals_ino4800_peer_review/","title":"Inovio Pharmaceuticals INO-4800 Peer Review Released. 100% Efficacy.","__typename":"SocialMediaPost","date":"December 24, 2020","parent":{"__typename":"RedditJson","localize":[{"title":"Inovio制药INO-4800同行评审发布。100%有效率。","the_new_excerpt":"刚刚被释放！\n\n*2毫克组细胞反应率为100%\n*一级不良反应=注射部位发红/红斑\n\nhttps://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30433-8/fulltext\n[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20]30433-8/fulltext)","locale":"zh"},{"title":"Inovio製藥INO-4800同行評審發佈。100%有效率。","the_new_excerpt":"剛剛被釋放！\n\n*2毫克組細胞反應率爲100%\n*一級不良反應=注射部位發紅/紅斑\n\nhttps://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30433-8/fulltext\n[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20]30433-8/fulltext)","locale":"zh-Hant"}]}}},"pageContext":{"id":"TweetPost-1341880899428888584","previousId":"TweetPost-1341931475260895236","nextId":"RedditPost-kjexi6","maxWidth":1024,"locale":"zh","hrefLang":"zh-Hans","originalPath":"/tweet/1341880899428888584","dateFormat":"YYYY-MM-DD"}},"staticQueryHashes":["1239077767","2506312863","2744905544","3493603132","3493603132","386998304","4203388852"]}